Member Info for spbhoy

Entirely different to what Avacta are doing and also at a very early stage:

In this study a type of therapy called targeted radionuclide therapy (TRT) will be used to treat patients with relapsed glioblastoma. The TRT in this study 123I-ATT001, contains two parts. A radioactive part that is radioactive iodine isotope and a chemical part, which can bind to specific targets (proteins) inside cancer cells to kill them while having a much weaker effect on healthy cells.

123I-ATT001 is a new experimental treatment, meaning it has not been approved by any regulatory authorities, such as the UK’s MHRA. This new treatment will only be available for those enrolled in this study. The study consists of two parts. Part 1 is a dose escalation study, where three doses of 123I-ATT001 will be tested, starting with the lowest dose. When the Data Monitoring Committee declare a recommend dose, an additional 8 patients will be recruited at that dose level in Part 1 of the study. In Part 2, one dose of 123I-ATT001 will be tested in a larger group of patients in combination with other therapies. Part 2 will begin after Part 1 has been completed

I had posted below but under a different thread:

the CITADEL-123 trial, surgeons remove as much tumour as possible before implanting a small medical device called an Ommaya reservoir under the scalp, which connects to the tumour via a small tube.

The nuclear medicine team at UCLH then inject a drug - ATT001, which helps repair DNA damage in cells - directly into the tumour to deliver small amounts of radioactivity.

The drug, given weekly for four to six weeks, causes lethal damage to tumour cells but leaves healthy tissue unaffected.

Only started July this year and also looks like it's only related to brain tumours.

Entirely different to what Avacta are doing and also at a very early stage:

In this study a type of therapy called targeted radionuclide therapy (TRT) will be used to treat patients with relapsed glioblastoma. The TRT in this study 123I-ATT001, contains two parts. A radioactive part that is radioactive iodine isotope and a chemical part, which can bind to specific targets (proteins) inside cancer cells to kill them while having a much weaker effect on healthy cells.

123I-ATT001 is a new experimental treatment, meaning it has not been approved by any regulatory authorities, such as the UK’s MHRA. This new treatment will only be available for those enrolled in this study. The study consists of two parts. Part 1 is a dose escalation study, where three doses of 123I-ATT001 will be tested, starting with the lowest dose. When the Data Monitoring Committee declare a recommend dose, an additional 8 patients will be recruited at that dose level in Part 1 of the study. In Part 2, one dose of 123I-ATT001 will be tested in a larger group of patients in combination with other therapies. Part 2 will begin after Part 1 has been completed

N the CITADEL-123 trial, surgeons remove as much tumour as possible before implanting a small medical device called an Ommaya reservoir under the scalp, which connects to the tumour via a small tube.

The nuclear medicine team at UCLH then inject a drug - ATT001, which helps repair DNA damage in cells - directly into the tumour to deliver small amounts of radioactivity.

The drug, given weekly for four to six weeks, causes lethal damage to tumour cells but leaves healthy tissue unaffected.

The platform and the pipeline will be presented at the investor and analyst R&D Spotlight Event: Focus on pre|CISION®, in London on October 30, 2024.

Looks like both connected at 1.7million shares exactly

Just curious as to why you have copied and pasted part of Myles recent Tweet. It's a great Tweet but you could just link to it instead

Https://avacta.com/wp-content/uploads/2024/10/FAP-AFFDC_Poster_SS44.09-2_v1.3-FINAL.pdf

Https://avacta.com/wp-content/uploads/2024/10/EORTC-NCI-AACR-poster-AVP103-v1_SS44.09_V1.1-updated-18.10.24-003.pdf

Cheers PL

@PL75...where is this quote from? I'm trying to check how I've missed it.

Reading up on when certain employees can trade shares, it really only specifies prior to regular financial updates as being the normal time that's restricted.. In addition, he's no longer on BOD and really just a stand in CFO until a replacement is introduced...no reason for him to be party to every detail of the trial data and/or any other matters.

Not sure what the relevance is of comparing to AVCT. I'm invested on both, and although my expectations for both are very positive, i cannot see how AGL Mcap being compared to AVCT Mcap makes any sense.

It's the second chunk of around £20k that he's bought in the ;last week or so. Strong signal indeed.

Most like Turner Pope choosing to exercise their's and perhaps some others from the August and/or previous raise. "Under the terms of the Placing Agreement, TPI will receive warrants to subscribe for 16,000,000 new Ordinary Shares ("Broker Warrants"). The Broker Warrants are exercisable at the Issue Price for a period of three years from the date of Admission. The Broker Warrants will not be admitted to trading on AIM or any other stock exchange.

Absolutely agree. Leaks in advance of a raise are rife on AIM. Thus not only slaughtering the SP in advance of a proposed raise, but jeopardising the raise in general from actually happening.

I'd actually say well done to them for being able to set this up in this way without the usual pre raise leakage or pre raise false pumping.....followed by SP getting slaughtered prior to announcing the raise. It also sounds like much of the placing is already agree with Insti Investors

Well, there's your answer

Been a long time since I looked in here, but no surprise to see Egleton is till milking this for all it's worth. Utter parasite